Serratus vs ESP Block for Postoperative Pain in Unilateral Breast Surgery

ConditionsPost Operative Pain Opioid Use

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age18-65

SponsorEngin Çetin

About this trial

This prospective, randomized, assessor-blinded trial compares serratus posterior superior intercostal plane block (SPSIPB) and erector spinae plane block (ESPB) for postoperative analgesia in unilateral breast surgery. 54 patients will be randomized to receive either SPSIPB or ESPB before general anesthesia.

The primary outcome is postoperative pain scores within the first 24 hours. The secondary outcome is opioid consumption.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female patients aged 18-65 years

ASA physical status I-III

Body mass index (BMI) between 18 and 35 kg/m²

Scheduled for elective unilateral breast surgery (mastectomy with or without sentinel lymph node biopsy)

Disqualifiers

Infection at the site of block application

Known allergy to local anesthetics

Coagulopathy or anticoagulant therapy

Chronic opioid use

Trial design

Design model

Parallel

Treatments tested in this trial

Serratus Posterior Superior Intercostal Plane Block
Procedure/Surgery
An ultrasound-guided interfascial plane block performed between the serratus posterior superior muscle and the underlying ribs prior to general anesthesia.

Treatment groups

54 Participants

are divided into 2 treatment groups

Group A: SPSIP BlockActive comparator 1 intervention

Group B: ESPB BlockActive comparator 1 intervention

Trial outcomes

Primary outcomes

Postoperative Pain Scores (NRS)

Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS; 0-10, where 0 indicates no pain and 10 indicates worst imaginable pain). Pain scores will be evaluated both at rest and during movement (coughing)

Time frame

T0: upon arrival at recovery (Aldrete ≥9), T1: 1 hour, T2: 4 hours, T3: 8 hours, T4: 12 hours, T5: 24 hours postoperatively

Secondary outcomes

Total Opioid Consumption

Total opioid consumption will be recorded during the first 24 hours postoperatively and expressed as intravenous tramadol consumption.

Time frame

T0-T1: 0-1 hour, T1-T2: 1-4 hours, T2-T3: 4-8 hours, T3-T4: 8-12 hours, and T4-T5: 12-24 hours postoperatively

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Engin Çetin

Lead sponsor

Kocaeli City Hospital

Sponsor institution

Source ClinicalTrials.gov

Apply now